Nivolumab/cabozantinib combination recommended for EMA approval for first-line kidney cancer
The Committee for Medicinal Products for Human Use (CHMP) of [...]
The Committee for Medicinal Products for Human Use (CHMP) of [...]
The past couple of years has seen a number of [...]
The microbes in the gut (the gut microbiome) are a [...]
This study compared disease outcomes, treatments, and dose reductions in [...]
A recent retrospective study (looking back at the patients’ cases [...]
Non-clear cell renal cell carcinoma (RCC) accounts for about 25% [...]
At the European Society of Medical Oncology (ESMO) Virtual Congress [...]
Over the past 2 years, the use of combination therapies [...]
A phase II study published in Frontiers in Oncology last [...]
In this video presentation, Dr Toni Chouieri discusses the SAVOIR, [...]